A recently-published study (New England Journal of Medicine, Nov. 21) describes a new vaccine that can prevent persistent infection from a virus HPV, the human papillomavirus known to be a causative factor in about one-half of all cases of cervical cancer. This is a major breakthrough, for the fight against cervical cancer and, more broadly, for the burgeoning field of pharmaceutical products that may be useful in preventing human cancer.
Cervical Cancer
A recently-published study (New England Journal of Medicine, Nov. 21) describes a new vaccine that can prevent persistent infection from a virus HPV, the human papillomavirus known to be a causative factor in about one-half of all cases of cervical cancer. This is a major breakthrough, for the fight against cervical cancer and, more broadly, for the burgeoning field of pharmaceutical products that may be useful in preventing human cancer.
Cervical Cancer